Pharmaceutical

Seres’ SER-155 gains breakthrough status for BSIs reduction

Seres Therapeutics has received US FDA breakthrough therapy designation for its SER-155, aimed at decreasing BSIs.

Dec 11, 2024 - 06:00
Seres’ SER-155 gains breakthrough status for BSIs reduction
Seres Therapeutics has received US FDA breakthrough therapy designation for its SER-155, aimed at decreasing BSIs.
Read the original article

Tags:

Previous Article

Santhera’s DMD therapy Agamree approved for NHS use after new price deal

Next Article

FDA to review GSK’s Nucala for COPD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Radiology captures the tension between AI’s potential and concern for patients

STAT+: Radiology captures the tension between AI’s pote...

Dec 1, 2023

Opinion: How learning the truth about chaos theory has helped me as an inpatient child psychologist

Opinion: How learning the truth about chaos theory has ...

Aug 31, 2023

Angle signs AstraZeneca deal to develop prostate cancer assay

Angle signs AstraZeneca deal to develop prostate cancer...

May 5, 2024